Revvity, Inc. Files 8-K on Agreement Termination & Financial Obligation
Ticker: RVTY · Form: 8-K · Filed: Jan 7, 2025 · CIK: 31791
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, corporate-actions
TL;DR
Revvity terminated a deal and took on new debt, filing an 8-K on Jan 7, 2025.
AI Summary
On January 7, 2025, Revvity, Inc. filed an 8-K report detailing the termination of a material definitive agreement and the creation of a direct financial obligation. The company, formerly known as PerkinElmer Inc., is based in Waltham, MA.
Why It Matters
This filing indicates significant changes in Revvity's contractual and financial standing, which could impact its future operations and financial obligations.
Risk Assessment
Risk Level: medium — The termination of a material definitive agreement and the creation of a new financial obligation suggest potential shifts in the company's business strategy or financial health.
Key Players & Entities
- Revvity, Inc. (company) — Registrant
- January 7, 2025 (date) — Date of earliest event reported
- PerkinElmer Inc. (company) — Former company name
- Waltham, MA (location) — Company business address
FAQ
What specific material definitive agreement was terminated by Revvity, Inc.?
The filing does not specify the details of the material definitive agreement that was terminated.
What is the nature of the direct financial obligation created by Revvity, Inc.?
The filing indicates the creation of a direct financial obligation but does not provide specific details about its nature or terms.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 7, 2025.
What were Revvity, Inc.'s former names?
Revvity, Inc. was formerly known as PerkinElmer Inc., EG&G Inc., and Edgerton Germeshausen & Grier Inc.
What is Revvity, Inc.'s SIC code and industry?
Revvity, Inc.'s SIC code is 3826, and its industry is Laboratory Analytical Instruments.
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2025-01-07 16:36:04
Key Financial Figures
- $1 — nge on which registered Common stock, $1 par value per share RVTY The New Yo
- $1.5 billion — rs. The Credit Agreement provides for a $1.5 billion committed unsecured revolving credit fa
- $4.2 million — 5, the Borrowers have no borrowings and $4.2 million of letters of credit outstanding under
Filing Documents
- d915642d8k.htm (8-K) — 33KB
- d915642dex991.htm (EX-99.1) — 1092KB
- 0001193125-25-002871.txt ( ) — 1503KB
- pki-20250107.xsd (EX-101.SCH) — 4KB
- pki-20250107_def.xml (EX-101.DEF) — 13KB
- pki-20250107_lab.xml (EX-101.LAB) — 21KB
- pki-20250107_pre.xml (EX-101.PRE) — 14KB
- d915642d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. EXHIBIT INDEX Exhibit No. Description 99.1 Credit Agreement, dated as of January 7, 2025, among Revvity, Inc. and Revvity Health Sciences, Inc. as Borrowers, Bank of America, N.A. as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVVITY, INC. Date: January 7, 2025 By: /s/ John L. Healy John L. Healy Vice President and Assistant Secretary